{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T20:28:18Z","timestamp":1781987298608,"version":"3.54.5"},"reference-count":35,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Background: Selecting the optimal oral anticoagulation (OAC) therapy for elderly patients with atrial fibrillation (AF) remains challenging. Our real-world study investigates clinical factors guiding OAC prescription patterns and compares outcomes between full- and reduced-dose direct-acting oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) in this demographic. Methods: This post hoc analysis of the MISOAC-AF trial focused on hospitalized AF patients aged \u2265 75 years prescribed OAC at discharge. Predictors of VKA and reduced DOAC dosing were identified using adjusted odds ratios (aORs). Cox regression models calculated adjusted hazard ratios (aHRs) for primary (all-cause mortality) and secondary outcomes (stroke, bleeding, AF or heart failure hospitalization, cardiovascular death). Results: Among 450 elderly patients, 63.6% received DOACs and 36.4% received VKAs. Higher CHA2DS2-VASc and HAS-BLED scores and antiplatelet use predicted VKA prescription. Hypertension, prior stroke, and bleeding history favored DOAC use. Advanced age and chronic kidney disease correlated with reduced DOAC dosing. Over a 3.7-year follow-up period, there was no significant difference in all-cause mortality between the DOAC and VKA groups (aHR 0.79, 95% CI 0.58\u20131.06) or between the full-dose and reduced-dose DOAC groups (aHR 0.96, 95% CI 0.60\u20131.53). Secondary analyses also did not yield statistically significant results in either comparison. Conclusions: Clinical profile parameters in elderly AF patients predict VKA or DOAC use. Clinical outcomes were similar between different OAC therapies.<\/jats:p>","DOI":"10.3390\/jcdd12030086","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T08:28:31Z","timestamp":1740558511000},"page":"86","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oral Anticoagulation Choice and Dosage in Very Elderly Patients with Atrial Fibrillation"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3044-3708","authenticated-orcid":false,"given":"Martha","family":"Zergioti","sequence":"first","affiliation":[{"name":"Medical School, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0011-2529","authenticated-orcid":false,"given":"Melina","family":"Kyriakou","sequence":"additional","affiliation":[{"name":"Medical School, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4981-8121","authenticated-orcid":false,"given":"Andreas S.","family":"Papazoglou","sequence":"additional","affiliation":[{"name":"Medical School, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1170-9133","authenticated-orcid":false,"given":"Anastasios","family":"Kartas","sequence":"additional","affiliation":[{"name":"Medical School, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios V.","family":"Moysidis","sequence":"additional","affiliation":[{"name":"424 General Hospital of Thessaloniki, 56429 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Samaras","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Hippokration Hospital of Thessaloniki, 54643 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8328-5942","authenticated-orcid":false,"given":"Efstratios","family":"Karagiannidis","sequence":"additional","affiliation":[{"name":"424 General Hospital of Thessaloniki, 56429 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8424-6718","authenticated-orcid":false,"given":"Vasileios","family":"Kamperidis","sequence":"additional","affiliation":[{"name":"Medical School, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"},{"name":"First Department of Cardiology, AHEPA University Hospital of Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Ziakas","sequence":"additional","affiliation":[{"name":"Medical School, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"},{"name":"First Department of Cardiology, AHEPA University Hospital of Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7491-6319","authenticated-orcid":false,"given":"George","family":"Giannakoulas","sequence":"additional","affiliation":[{"name":"Medical School, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"},{"name":"First Department of Cardiology, AHEPA University Hospital of Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1747493019897870","article-title":"Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge","volume":"16","author":"Lippi","year":"2021","journal-title":"Int. J. Stroke"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","article-title":"Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates","volume":"82","author":"Kannel","year":"1998","journal-title":"Am. J. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12933-022-01473-0","article-title":"Glycemic control and atrial fibrillation: An intricate relationship, yet under investigation","volume":"21","author":"Papazoglou","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_5","first-page":"341","article-title":"Anticoagulant treatment in elderly patients with atrial fibrillation: A position paper","volume":"17","author":"Hanon","year":"2019","journal-title":"Geriatr. Psychol. Neuropsychiatr. Vieil."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/europace\/euw295","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"18","author":"Kirchhof","year":"2016","journal-title":"Europace"},{"key":"ref_7","first-page":"16508","article-title":"Oral anticoagulation challenges and therapeutic dilemmas in the very elderly: To treat and how to treat octogenarians and nonagenarians?","volume":"133","author":"Papazoglou","year":"2023","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/ageing\/afaa045","article-title":"Factors associated with non-prescription of oral anticoagulant treatment in non-valvular atrial fibrillation patients with dementia: A CPRD-HES study","volume":"49","author":"Besford","year":"2020","journal-title":"Age Ageing"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/jgs.16335","article-title":"Geriatric Conditions Predict Discontinuation of Anticoagulation in Long-Term Care Residents With Atrial Fibrillation","volume":"68","author":"Kapoor","year":"2020","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacasi.2022.07.008","article-title":"Oral Anticoagulants in Very Elderly Nonvalvular Atrial Fibrillation Patients With High Bleeding Risks: ANAFIE Registry","volume":"2","author":"Okumura","year":"2022","journal-title":"JACC Asia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jjcc.2018.01.015","article-title":"Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: A systematic review and meta-analysis","volume":"72","author":"Kim","year":"2018","journal-title":"J. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kim, H.M., Choi, E.K., Park, C.S., Cha, M.-J., Lee, S.-Y., Kwon, J.-M., and Oh, S. (2019). Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0211766"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/jgs.15430","article-title":"Dabigatran, Rivaroxaban, and Warfarin in the Oldest Adults with Atrial Fibrillation in Taiwan","volume":"66","author":"Lai","year":"2018","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e001768","DOI":"10.1136\/bmjopen-2012-001768","article-title":"Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: A cross-sectional analysis using the General Practice Research Database","volume":"2","author":"Lee","year":"2012","journal-title":"BMJ Open"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.4022\/jafib.1870","article-title":"What is the Impact of Frailty on Prescription of Anticoagulation in Elderly Patients with Atrial Fibrillation? A Systematic Review and Meta-Analysis","volume":"10","author":"Oqab","year":"2018","journal-title":"J. Atr. Fibrillation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.hjc.2020.02.007","article-title":"Rationale and design of a randomized study comparing Motivational Interviewing to Support Oral Anticoagulation adherence versus usual care in patients with nonvalvular atrial fibrillation: The MISOAC-AF trial","volume":"61","author":"Samaras","year":"2020","journal-title":"Hell. J. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"f63","DOI":"10.1093\/ehjcvp\/pvaa039","article-title":"Motivational Interviewing to Support Oral AntiCoagulation adherence in patients with non-valvular Atrial Fibrillation (MISOAC-AF): A randomized clinical trial","volume":"7","author":"Tzikas","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jjcc.2022.09.009","article-title":"Prognostic implications of adherence to oral anticoagulants among patients with atrial fibrillation: Insights from MISOAC-AF trial","volume":"81","author":"Patsiou","year":"2023","journal-title":"J. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.archger.2018.12.013","article-title":"Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis","volume":"81","author":"Caldeira","year":"2019","journal-title":"Arch. Gerontol. Geriatr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e005657","DOI":"10.1161\/JAHA.117.005657","article-title":"Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (PREvention oF Thromboembolic Events\u2013European Registry in Atrial Fibrillation)","volume":"6","author":"Patti","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","article-title":"Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)","volume":"130","author":"Halperin","year":"2014","journal-title":"Circulation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: Observations from the ARISTOTLE trial","volume":"35","author":"Halvorsen","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus Warfarin in Patients with Atrial Fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Poli, D., Antonucci, E., Ageno, W., Bert\u00f9, L., Migliaccio, L., Martinese, L., Pilato, G., Testa, S., and Palareti, G. (2019). Oral anticoagulation in very elderly patients with atrial fibrillation: Results from the prospective multicenter START2-REGISTER study. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216831"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/heartjnl-2020-318753","article-title":"Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation","volume":"108","author":"Rutherford","year":"2022","journal-title":"Heart"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus Warfarin in Patients with Atrial Fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_30","first-page":"279","article-title":"Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial","volume":"149","author":"Joosten","year":"2024","journal-title":"Circulation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2147\/CIA.S453527","article-title":"Effects of Anticoagulant Therapy and Frailty in the Elderly Patients with Atrial Fibrillation","volume":"19","author":"Ding","year":"2024","journal-title":"Clin. Interv. Aging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jacc.2020.07.045","article-title":"Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants","volume":"76","author":"Camm","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1074248418821712","article-title":"Flaws in Anticoagulation Strategies in Patients With Atrial Fibrillation at Hospital Discharge","volume":"24","author":"Kartas","year":"2019","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11239-020-02167-8","article-title":"Right drug, wrong dosage: Insights from the PAVE-AF antithrombotic study in older patients with atrial fibrillation","volume":"51","author":"Tzeis","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1080\/07853890.2022.2117407","article-title":"The role of prognostic stratification on prescription of anticoagulants in older patients with atrial fibrillation: A multicenter, observational, prospective European study (EUROSAF)","volume":"54","author":"Pilotto","year":"2022","journal-title":"Ann. Med."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/12\/3\/86\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:42:41Z","timestamp":1760028161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/12\/3\/86"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcdd12030086"],"URL":"https:\/\/doi.org\/10.3390\/jcdd12030086","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]}}}